Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ACLS THER

Market Cap 60Cr 52Cr 48Cr 45Cr 84Cr 5.73TCr 86Cr 567.01Cr 221.07Cr 2.79TCr 226.44Cr 221.62Cr 9.67TCr P/E Ratio 2026 *
-6.66x
P/E Ratio 2027 * -5.42x
Enterprise Value 47Cr 40Cr 37Cr 35Cr 65Cr 4.45TCr 66Cr 439.58Cr 171.39Cr 2.16TCr 175.55Cr 171.81Cr 7.49TCr EV / Sales 2026 *
81.9x
EV / Sales 2027 * 89.3x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 17/01/2024
President 67 18/11/2024
Director of Finance/CFO 39 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2023
Chairman 60 01/06/2019
Director/Board Member 50 01/09/2014
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%+2.30%+55.91%+114.22% 5.64TCr
+2.72%+3.26%+46.05%+44.91% 4.45TCr
+1.12%+2.79%-15.04%-21.68% 2.29TCr
+1.17%+3.85%-0.89%+403.86% 2.12TCr
+3.81%-5.07%+11.00%-30.62% 1.64TCr
+0.15%+2.24%+9.32%-39.30% 1.54TCr
-0.69%+0.82%+27.75%+176.72% 1.34TCr
+5.27%+5.54%+19.65% - 1.24TCr
+1.61%+1.28%+95.75%+205.26% 1.12TCr
Average +1.80%+2.09%+27.72%+106.67% 2.37TCr
Weighted average by Cap. +1.72%+2.37%+32.04%+99.60%

Financials

2026 *2027 *
Net sales 57.13L 49.34L 45.47L 42.56L 79.76L 54Cr 80.99L 5.37Cr 2.09Cr 26Cr 2.14Cr 2.1Cr 92Cr 53.58L 46.28L 42.65L 39.92L 74.81L 51Cr 75.97L 5.04Cr 1.96Cr 25Cr 2.01Cr 1.97Cr 86Cr
Net income -8.48Cr -7.32Cr -6.75Cr -6.32Cr -12Cr -805.86Cr -12Cr -80Cr -31Cr -392.24Cr -32Cr -31Cr -1.36TCr -10Cr -8.85Cr -8.16Cr -7.64Cr -14Cr -974.4Cr -15Cr -96Cr -38Cr -474.28Cr -38Cr -38Cr -1.64TCr
Net Debt -14Cr -12Cr -11Cr -10Cr -19Cr -1.29TCr -19Cr -127.43Cr -50Cr -627.35Cr -51Cr -50Cr -2.17TCr -12Cr -11Cr -9.94Cr -9.31Cr -17Cr -1.19TCr -18Cr -117.38Cr -46Cr -577.85Cr -47Cr -46Cr -2TCr
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!